… post-hoc analyses suggested a possible continued treatment effect of edaravone and
maintenance of long-term efficacy … long-term safety and efficacy of edaravone in patients with ALS. …

… Based on this post-hoc analysis, we conclude that edaravone shows a statistically significant
reduction in the rate of disease progression in subjects with FVC <80%p, providing benefit …

… The efficacy of edaravone against ALS was not demonstrated in this trial, although a
hypothesis-driven post-hoc analysis suggested that edaravone was efficacious in a restricted …

… Post-hoc analysis of these data … this post-hoc result and assess safety and efficacy of
edaravone in a phase 3 trial that focused on patients with early stage ALS who met the post-hoc …

… Abstract Our first phase III study failed to demonstrate efficacy of edaravone for … post-hoc
subgroup analysis to identify a subgroup in which edaravone might be expected to show efficacy…

… did not demonstrate statistical superiority to placebo for the primary efficacy … post-hoc
exploratory analyses were conducted to identify a subpopulation in which efficacy of edaravone …

… The clinical development program for edaravone in ALS focused on testing the drug’s
efficacy in a relatively short time frame (ie 24 weeks). An overview of this program is shown in …

… placebo for the primary efficacy endpoint. For post-hoc analyses, two subpopulations
were identified in which edaravone might be expected to show efficacy: the efficacy-expected …

… The first 3 trials failed to reach the primary end point; however, post hoc analysis of the … In
summary, evidence for the efficacy of edaravone in the treatment of patients with ALS is limited …

… that edaravone shows promising efficacy in terms … edaravone failed to demonstrate the
efficacy of this drug in the treatment of ALS, post hoc analysis revealed the efficacy of edaravone …